BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Baruch D. Kuppermann, MD, PhD, comments on the decision of the European Medicines Agency to reject the appeal for the approval of pegcetacoplan.
He sympathizes with the disappointment of his European colleagues who have been denied access to a pharmacotherapy that can benefit patients with geographic atrophy.
Like most retina specialists in the U.S., Kuppermann uses both Syfovre (pegcetacoplan injection, Apellis Pharmaceuticals) and Izervay (avacincaptad pegol intravitreal solution, Astellas Pharma), but he